My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-Mouse 4-1BB Monoclonal Antibodies

Anti-Mouse 4-1BB Monoclonal Antibodies

cluster of differentiation 137, CD137, TNFRSF9

Catalog No. Product Name Size List Price (US$) Quantity
PA007276.r2a In vivo Grade Recombinant Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody (Clone: 3H3), Rat IgG2a Kappa 1 mg 150.00
PA007276.r2a In vivo Grade Recombinant Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody (Clone: 3H3), Rat IgG2a Kappa 5 mg 350.00
PA007276.r2a In vivo Grade Recombinant Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody (Clone: 3H3), Rat IgG2a Kappa 25 mg 900.00
Description

PA007276.r2a: In vivo Grade Recombinant Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody, Rat IgG2a Kappa (Clone: 3H3)

Recombinant rat IgG2a Monoclonal Antibody. 
Clone: 3H3.
Isotype: Rat IgG2a kappa.
Source: The anti-mouse CD137 (TNFRSF9 or 4-1BB) monoclonal antibody (clone: 3H3) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 3H3) specifically binds to the mouse 4-1BB protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse 4-1BB protein. 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

The 3H3 antibody binds to 4-1BB (TNFRSF9 or CD137), one representative TNF receptor family co-stimulatory receptor. The 4-1BB protein is expressed on a wide variety of cell types, including activated T cells, NK cells, DCs, B cells, monocytes, and neutrophils. Anti-4-1BB-induced CD8+ T responses play a dominant role in anti-tumor immunity, such as induction of more effector molecules released from CD8+ T cells, increased proliferation and decreased apoptosis of CD8+ T cells.

References of Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody:

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
Qi, X., et al. Nat Commun. 2019 May 20;10(1):2141. doi: 10.1038/s41467-019-10088-1. PMID: 31105267
Both LOB12.3 and 3H3 Abs showed anti-tumor efficacy (Fig. 1a, b) but they exhibited distinct liver toxicity profiles; 3H3 significantly increased alanine transaminase (ALT) levels, whereas LOB12.3 had minimal impact on ALT levels. ...We, therefore, used LOB12.3 and 3H3 Abs as tool molecules to investigate the underlying mechanism in order to gain insights for clinical development of agonistic anti-4-1BB Abs. ...Surprisingly, only 3H3 showed a co-stimulatory effect, suggesting the co-stimulatory ability of 3H3 does not depend on non-T cells while that of LOB12.3 requires help from other cells. ...To test whether anti-4-1BB treatment could generate anti-tumor memory responses, we challenged cured mice with lethal dosage of CT-26 tumor cells. ...To test this idea, we compared the anti-tumor activity of LOB12.3-mIgG1, LOB12.3-mIgG2a, 3H3-mIgG1, and 3H3-mIgG2a.
Tags: anti-mouse CD137 (TNFRSF9 or 4-1BB) 3H3 mAb; anti-mouse CD137 (TNFRSF9 or 4-1BB) 3H3 antibody in vivo

Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.
Verbrugge, I., et al. Cancer Res. 2012 Jul 1;72(13):3163-74. doi: 10.1158/0008-5472.CAN-12-0210. PMID: 22570253
In addition, radiotherapy has been trialed in conjunction with monoclonal antibodies (mAb) that target costimulatory molecules such as CD40, CD137, OX40 (CD134), or the checkpoint inhibitor CTLA-4. ...Blockade of immune checkpoint-inhibitory molecules such as CTLA-4 or programmed death (PD)-1, alone or in combination with anti-(α)-CD137 therapy also increased the therapeutic activity of vaccine approaches and α-erbB2 therapy. ...Here, we show that mAbs to CD137, CD40, and PD-1, which are all in clinical development, combined with single- and low-dose fractionated radiotherapy, induced the rejection of established subcutaneous and orthotopically implanted, triple-negative [estrogen receptor (ER)−, Her2/neu− and progesterone receptor (PR)−] AT-3 and 4T1.2 mammary tumors. ...These cells expressed CD137 and/or PD-1 and persisted within the irradiated tumors. ...The rat mAb to mouse CD137 (3H3, IgG2a) was generated in house as described (28) and protein-G purified or purchased from BioXCell.
Tags: anti-mouse CD137 (TNFRSF9 or 4-1BB) 3H3 mAb in animal model; anti-mouse CD137 (TNFRSF9 or 4-1BB) 3H3 in cancer research

For more references about Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
Recombinant rat lgG2a isotype control antibody
Recombinant human IgG1 isotype control antibodies

Syd Labs provides the following anti-mouse 4-1BB antibodies:
Anti-mouse 4-1BB monoclonal antibody (Clone: LOB12.3)

Related Links

See our Privacy Policy